Cited by 395SARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug ReactionsVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Maintaining Safety with SARS-CoV-2 Vaccines

Open access

Castells, Mariana C., Phillips, Elizabeth J.·2021·New England Journal of Medicine

DOI 10.1056/nejmra2035343PMC PMC7787218

Open this paper in CoChat — free account

Abstract

The following table lists substances, other than active ingredients (i.e., antigens), shown in the manufacturers' package insert (PI) as being contained in the final formulation of each vaccine.Substances used in the manufacture of a vaccine but not listed as contained in the final product (e.g., culture media) can be found in each PI, but are not shown on this table.Each PI, which can be found on the FDA's website (see below) contains a description of that vaccine's manufacturing process, including the amount and purpose of each substance.In most PIs, this information is found in Section 11: "Description." Please refer to the PI for a complete list of ingredients or excipients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmra2035343

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
A global survey of potential acceptance of a COVID-19 vaccine
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021) · Nature Medicine · doi:10.1038/s41591-020-1124-9 · Cited by 2,904
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II
Freeman, D. H., Loe, B. S., Chadwick, A., Vaccari, C., Waite, F., Rosebrock, L. E., Jenner, L., Petit, A., Lewandowsky, S., Vanderslott, S., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720005188 · Cited by 802
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized
Stone, C. A., Liu, Y., Relling, M. V., Krantz, M. S., Pratt, A. L., Abreo, A. M., Hemler, J. A., & Phillips, E. J. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.12.003 · Cited by 349
Anaphylaxis
Bochner, B. S., & Lichtenstein, L. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106203242506 · Cited by 324

Show all 17 references

Sorted by citations

Items 301–395 of 395

Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects
Feng, G., Zhang, L., Wang, K., Chen, B., & Xia, H. H. (2021) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2021.00004 · Cited by 3
A Transient Initiator for Polypeptoids Postpolymerization α ‐Functionalization via Activation of a Thioester Group
Borova, S., Schlutt, C., Nickel, J., & Luxenhofer, R. (2021) · Macromolecular Chemistry and Physics · doi:10.1002/macp.202100331 · Cited by 3
COVID-19 Vaccinating Russian Medical Students—Challenges and Solutions: A Cross-Sectional Study
Kytko, O. V., Vasil’ev, Y. L., Dydykin, S. S., Diachkova, E. Y., Sankova, M. V., Litvinova, T. M., Volel, B. A., Zhandarov, K. A., Grishin, A. A., Татаркин, В. В., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811556 · Cited by 4
Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination
Petrelli, F., Giannini, D., Pucci, C., Corso, I. D., Rocchi, V., Dolcher, M. P., Pieve, G., Pratesi, F., Migliorini, P., & Puxeddu, I. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000526764 · Cited by 3
A practical guide to address reactions to vaccines in children
Arcolacı, A., Scarmozzino, R., & Zanoni, G. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13967 · Cited by 3
Potential anaphylactoid reaction to nicardipine
Hassan, A., Hill, H., Donley, C., & Leonelli, C. (2024) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.13271 · Cited by 3
Ionic co-aggregates based intravenous drug delivery: Evaluation on kinetics and distribution of the drug payloads and nanocarriers
Sheng, Y., Zheng, X., Li, L., He, H., Wu, W., & Lü, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124657 · Cited by 3
Coronavirus disease 2019 vaccines: perspectives and update
Kaushik, S. K., Bobdey, S., Faujdar, D. S., Anand, V. R., & Yadav, A. K. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.04.003 · Cited by 3
“However, anaphylaxis reaction has been notedwith the incidence of 1 in 100,000 doses, which is ten times than with previously known vaccine, which has been attributed to polyethylene glycol in LNP.(23)”
BackgroundInfluential
An update on COVID-19 outbreak: The longest pandemic
Mahor, S., Chadha, H., Prajapati, S., Mishra, S. K., & Ojha, S. (2022) · Biological Sciences · doi:10.55006/biolsciences.2022.2102 · Cited by 3
COVID-19 vaccine provocation test outcome in high-risk allergic patients: A retrospective study from a tertiary hospital in Indonesia
Koesnoe, S., Maria, S., Widhani, A., Hasibuan, A. S., Karjadi, T. H., Khoirunnisa, D., Yusuf, M., Sumariyono, S., Liastuti, L. D., Djauzi, S., et al. (2022) · World Allergy Organization Journal · doi:10.1016/j.waojou.2022.100734 · Cited by 3
SARS-CoV-2 Vaccination for Children—An Open Issue
Caselli, D., & Aricò, M. (2021) · Pediatric Reports · doi:10.3390/pediatric13010013 · Cited by 4
“Based on the above considerations, we have to preserve safety of vaccinations [25], not to expose this precious public health weapon to the queries of no-vax and negationists.”
Background
Inmunización para la COVID-19. Diferencias en la tecnología de producción, eficacia y seguridad
Marco, J. J. G., Martínez, A. M., & Bermejo, L. F. (2021) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2021.06.001 · Cited by 3
A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease
Wu, Y., & Song, H. X. (2022) · Life · doi:10.3390/life12010130 · Cited by 6
“These vaccines have thus far been proven safe, with no serious side effects reported yet [19].”
Background
Transient Myopericarditis Following Vaccination for COVID-19
Gill, J., Mallari, A. J. P., & Zahra, F. (2022) · Journal of Medical Cases · doi:10.14740/jmc3876 · Cited by 3
Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
Diogo, P., Correia, G., Martins, J. F. B., Soares, R., Palma, P., Santos, J. M., & Gonçalves, T. (2022) · Vaccines · doi:10.3390/vaccines10040602 · Cited by 3
Use of antihistamines for COVID-19 vaccine recipients with risk of anaphylaxis
Grabowski, J., Wolff, M., Pettersson, S. D., Brancewicz, T., & Bidzan, L. (2022) · European Journal of Translational and Clinical Medicine · doi:10.31373/ejtcm/138219 · Cited by 3
“Since mRNA vaccines are novel products, the exact mechanism or the root cause of the allergic reaction associated with them is unknown [9].”
Background
COVID-19-Related Predictors of Fear and Attitude to Vaccination Displayed by Polish Students
Bartosiewicz, A., Łuszczki, E., Bartosiewicz, A., Dereń, K., Oleksy, Ł., & Stolarczyk, A. (2022) · Vaccines · doi:10.3390/vaccines10091524 · Cited by 3
“However, for this method to be effective, public acceptance of vaccines and willingness of people to get vaccinated are necessary [8,12].”
Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein
Zhou, Y.-F., Nie, J., Shi, C., Ning, K., Cao, Y., Xie, Y., Xiang, H., & Xie, Q. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2205.05023 · Cited by 3
“There is no doubt that the development of these two vaccines was successful, both in terms of safety and immunogenicity [12], but we cannot ignore the huge difficulties in transportation, which presents a huge challenge for mass vaccination on a global scale [13].”
Background
Enhancing the Antitumor Efficacy of Zwitterionic Peptide-Based Nanoscale Micelles through Sensitizing Their Response in Solid Tumors
Wei, X., Xiang, Z., Xue, W., & Chen, S. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c03880 · Cited by 3
It’s time for an evolution
Pawankar, R. (2021) · Asia Pacific Allergy · doi:10.5415/apallergy.2021.11.e11 · Cited by 3
“org/) including information on the vaccines and guidance on the adverse effects and safety issues of the vaccine [6].”
Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily reportPreprint
Binay, U. D., Karakeçili, F., Barkay, O., Gül, Ö., & Mertoğlu, C. (2021) · Research Square · doi:10.21203/rs.3.rs-388073/v1 · Cited by 3
“Anaphylaxis is one of the important life-threatening side effects and there are concerns that it may be more likely to be seen in mRNA vaccines [12,18-20].”
Background
In vivo metabolic pathways and tissue distribution of pharmaceutical excipient polysorbate 80 using ultra-high performance liquid chromatography-high resolution mass spectrometry analysis
Wang, Z., Sun, Y., Li, X., Liu, Q., & Zhang, J. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107208 · Cited by 2
Making US poison centers a part of the solution to the COVID-19 pandemic
Spyker, D. A., Bronstein, A. C., & Weber, J. A. (2021) · Clinical Toxicology · doi:10.1080/15563650.2021.1933510 · Cited by 2
“The distribution of 3 COVID-19 vaccines has been authorized under EUAs in the US and another 3 are expected in the next few months [11] (Table 4).”
Background
Potential role of hyperimmune milk as a source of passive immunotherapy against COVID-19: A review
Singh, P., Ghatak, S., Kumar, P., & Mehta, N. R. (2023) · International Dairy Journal · doi:10.1016/j.idairyj.2023.105765 · Cited by 2
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy
Nicola, S., Mazzola, M., Sardo, L. L., Montabone, E., Badiu, I., Corradi, F., Azzolina, M. C. R., Dall’Acqua, M. G., Rolla, G., Ridolfi, I., et al. (2024) · Vaccines · doi:10.3390/vaccines12020202 · Cited by 2
“However, in the first few months, some cases of vaccines-related hypersensitivity reactions were observed [7] and worries about the safety of COVID-19 vaccines emerged [2].”
Background
How a Novel Approach of Allergy Call Center Improved the Management of the Anti-COVID Vaccination Campaign in Piedmont: Italy
Badiu, I., Nicola, S., Rashidy, N., Mura, S. D., Tarrini, D., Bernardi, V., Gallicchio, M., Ridolfi, I., Saracco, E., Montabone, E., et al. (2024) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-024-00309-2 · Cited by 2
“The risk of anaphylaxis after vaccination with Comirnaty has been reported to be higher than other non-covid vaccinations [3–5] and the allergic sensitization was attributed to both the vac-cine itself and its excipients [6–9].”
mRNA-based vaccines and therapies - a revolutionary approach for conquering fast-spreading infections and other clinical applications: a review
Pan, M., Cao, W., Zhai, J., Zheng, C., Xu, Y., & Zhang, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143134 · Cited by 2
Comparison of two currently available anti-COVID-19 vaccines
Pawliczak, R. (2021) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2021.102554 · Cited by 2
Thesenpapier 7.0 zur Pandemie durch SARS-CoV-2/Covid-19
al., S. E. (2021) · Monitor Versorgungsforschung · doi:10.24945/mvf.01.21.1866-0533.2283 · Cited by 2
Meningoradiculitis post-COVID-19 mRNA vaccination: A case report
Landry, A., Crapoulet, S., Boudreau, L. H., Bourque, C., Weston, L. E., Pilote, N., Desnoyers, G., & Chamard-Witkowski, L. (2022) · Clinical Immunology Communications · doi:10.1016/j.clicom.2022.03.004 · Cited by 2
[Translated article] Pleuropericardial Effusion and Systemic Inflammatory Syndrome Secondary to the Administration of the mRNA-1273 Vaccine for SARS-CoV-2
Boira, I., Torba, A., Castelló, C., Esteban, V., Vañes, S., & Chiner, E. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.01.021 · Cited by 2
Pharmacovigilance in Covid-19 vaccines
Bahouq, H., Bahouq, M., Soulaymani, A., & Bencheikh, R. S. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202131901012 · Cited by 2
A Case Report of Prolonged Anaphylaxis after COVID-19 Vaccine
Armstrong, L., & Maguire, N. (2021) · Clinical Practice and Cases in Emergency Medicine · doi:10.5811/cpcem.2021.9.53690 · Cited by 2
Immunization practices and risk of anaphylaxis: a current update, comprehensive of COVID-19 vaccination data
Arcolacı, A., Bronte, V., & Zanoni, G. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000769 · Cited by 2
Drug allergy biomarkers
Castells, M. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.10.017 · Cited by 2
Exploring the Therapeutic Potential of Defective Interfering Particles in Reducing the Replication of SARS-CoV-2
Locke, M., Grebennikov, D. S., SAZONOV, I. A., López‐García, M., Loguinova, M. Y., Meyerhans, A., Bocharov, G. A., & Molina-Parı́s, C. (2024) · Mathematics · doi:10.3390/math12121904 · Cited by 1
Pushing the Envelope
Young, S. K., Pollard, R. J., & Shapiro, F. E. (2021) · Advances in Anesthesia · doi:10.1016/j.aan.2021.07.006 · Cited by 1
“They have also been shown to be well tolerated, with rare but serious allergic reactions noted [63].”
Vaccination COVID en pneumologie.
Blanchard, E. J., Ozier, A., Janssen, C., Wyplosz, B., & Andréjak, C. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2021.07.003 · Cited by 1
Antiviral Effects of Mandarin Somatid Natural Gel on SARS-CoV-2 Infection in vitro
Kim, Y., Oh, E. Y., Park, S., & Lee, S. (2021) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2021.51.4.200 · Cited by 1
“Currently, various therapeutic candidates against SARS-CoV-2 are being developed and are being treated to people (3-6).”
Background
Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
Wei, Y., Wang, Y., Liu, J., Zha, Y., Yang, Y., Li, N., Zhou, Y., Zhu, J., Roberts, N., Liu, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10111869 · Cited by 1
“Severe adverse events were rare, and included hypersensitivity, facioplegia, urticaria, and anaphylactic shock [22].”
Background
Administration of the Second Dose of mRNA COVID-19 Vaccine to a Woman With Immediate Reaction to the First Dose
Apostolidou, E., Dimitriou, K., Papadopoulou, A., Mikos, N., & Kompoti, E. (2023) · Cureus · doi:10.7759/cureus.36064 · Cited by 2
“The tolerance of a second vaccination dose either doubts on the allergic nature of the reaction being reported after the initial dose, or supports an allergic, but non-IgE-mediated mechanism in which symptoms can typically be avoided with premedications [2].”
Background
Гіперчутливість до ексципієнтів лікарських засобів. Огляд літератури
Зайков, С. В., Bogomolov, A. Y., Gritsova, N. A., & Veselovsky, L. V. (2023) · Asthma and allergy · doi:10.31655/2307-3373-2023-1-51-62 · Cited by 1
The Prevalence of COVID Infection and Adverse Events Following Immunization with COVID-19 Vaccine (Covishield) Among Healthcare Workers and Students of a Dental College in Kerala: A Cross-sectional Study
Mathew, J., George, L. E., Paul, S., Joy, A., & Peradi, S. (2023) · Conservative Dentistry and Endodontic Journal · doi:10.5005/jp-journals-10048-0108 · Cited by 1
Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis
Hanafy, A. S., Embaby, A., Salem, S. M., Behiry, A., Ebrahim, H. A., Elkattawy, H. A., Abed, S. Y., Almadani, M. E., & El‐Sherbiny, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247578 · Cited by 1
“Polyethylene glycol is used for the stability of the lipid nanoparticles, which may occasionally result in anaphylaxis [12].”
Background
Furacin
Cuevas-Bravo, C., Quirós, J. C., Noguerado-Mellado, B., & Pérez‐Ezquerra, P. R. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.05.030 · Cited by 1
COVID-19 vaccine: Potential candidates, achievements, and challenges
Shoaib, M., Waheed, A., Wajid, M., Urwa, H., Khan, T. S., Khan, M. S., Aslam, M. W., Ahmad, S., Jafar, K., Akmal, H., et al. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.15.3.0145 · Cited by 1
“Threats Eight healthcare workers experienced serious allergic reactions after receiving both mRNA-based vaccines, but the scientists speculated that these serious allergic reactions may be related to anyone from polyethylene glycol or lipidbased nanoparticles in the vaccines, which are used to prolong their lifespan […”
Background
Antworten auf brennende Fragen an klinische Allergolog*innen im Zusammenhang mit den neuen COVID-19-Impfstoffen
Altrichter, S., Wöhrl, S., Horak, F., Idzko, M., Jordakieva, G., Untersmayr, E., Szépfalusi, Z., Zieglmayer, P. U., Jensen‐Jarolim, E., Wiedermann, U., et al. (2021) · Allergo Journal · doi:10.1007/s15007-021-4847-0 · Cited by 1
COVID-19 Vaccines: An Account of Need and Efficacy vs Safety and Challenges
Nag, A., Kalra, A., Sharma, H., Shringi, H., & Kumar, A. (2021) · LS International Journal of Life Sciences · doi:10.5958/2319-1198.2021.00010.5 · Cited by 1
Adverse events and preventive measures related to COVID-19 vaccines
Ahn, T. K., Kang, S. Y., Paik, J. H., & Seo, Y. H. (2021) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.21.067 · Cited by 1
“This lipid nanoparticle carrier system prevents the rapid enzymatic degradation of mRNA and facilitates in vivo delivery.(6) Because lipid nanoparticles are sensitive to temperature, this type of vaccine should be transported and stored under extremely low temperatures.”
Background
Safety of covid-19 vaccine prophylaxis: literature review and clinical experience of its implementation
Mamrovskaya, T. (2021) · Dalʹnevostočnyj medicinskij žurnal · doi:10.35177/1994-5191-2021-3-6-12 · Cited by 1
Anafilaxia causada por vacunas
Perea-Valle, P., Delgado-Aguirre, C. J., Villafuerte-Domínguez, B. G., & Del-Rio-Navarro, B. E. (2022) · Revista Alergia México · doi:10.29262/ram.v69isupl1.989 · Cited by 1
Derrame pleuropericárdico y síndrome inflamatorio sistémico secundario a la administración de vacuna ARNm-1273 para coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2)
Boira, I., Torba, A., Castelló, C., Esteban, V., Vañes, S., & Chiner, E. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.01.002 · Cited by 1
Potential impact of viral skin diseases and other viral infections on the incidence and severity of COVID-19 in renal transplant patients
Perlina, A. D., Alexandrov, I. V., Прокопенко, Е. И., Terentyev, A. V., & Kulikov, P. A. (2021) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2021-49-066 · Cited by 1
Prevention and Ethics
ten Have, H. (2022) · Advancing global bioethics · doi:10.1007/978-3-030-91491-2_8 · Cited by 1
Immunity to Viral Pathogens and the Virome
Carlberg, C., & Velleuer, E. (2022) · Springer eBooks · doi:10.1007/978-3-031-04025-2_8 · Cited by 1
Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
Ridolo, E., Pucciarini, F., Barone, A., & Incorvaia, C. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i5.13006 · Cited by 1
“As for the patients referred to our allergy clinic for immediate reaction following administration of the first or second dose, only in a small fraction (6 of almost 150 patients) we could prove PEG hypersensitivity.”
BackgroundInfluential
COVID-19 vaccines and the role of other potential allergenic components different from PEG.Preprint
Novak, N., Akdiş, C. A., & Cabanillas, B. (2021) · doi:10.22541/au.161157257.70920317/v1 · Cited by 1
COVID‐19: Filling the Many Knowledge Gaps and Supporting Evidence‐Based Vaccination
Dooley, M. J. (2021) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1717 · Cited by 1
[Development of standards and guidelines by the German Cancer Society].
Hermanek, P. (1999) · PubMed · Cited by 1
Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & HamstersPreprint
Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.02.482651 · Cited by 1
Le vaccin à ARN pour la COVID-19 – quel risque allergique ?
Demoly, P. M. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.01.020
Preventative and Proactive Measures to Mitigate the Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Preprint
Young, J., He, E. M., Boone, D., Luehr, J., Tasnim, K., Turner, M., Ambatipudi, M., Gonzalez, P. C., Mooney, D. J., & Koh, E. G. L. (2021) · doi:10.14293/s2199-1006.1.sor-.ppaahgk.v1
“Vaccines that allow for safe and effective immunization are another valuable mitigation method [11-13].”
Method
Drug Allergy Management on the Move
Demoly, P. M., & Ramsey, A. C. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.04.009
SARS-CoV-2-Impfstoffe und Reaktion des Immunsystems. Kann die epidemische Ausbreitung des Virus durch Impfung verhindert werden?
Schmidt, J., Blessing, F., & Gürtler, L. G. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1550-0001
Appropriate information provision about COVID-19 and SARS-CoV-2 vaccine improves vaccination anxiety in patients with autoimmune liver disease
Kakisaka, K., Suzuki, Y., Yoshida, Y., & Takikawa, Y. (2021) · Kanzo · doi:10.2957/kanzo.62.613
An intranasal lentiviral booster broadens immune recognition of SARS-CoV-2 variants and reinforces the waning mRNA vaccine-induced immunity that it targets to lung mucosaPreprint
Vesin, B., Lopez, J., Noirat, A., Authié, P., Fert, I., le Chevalier, F., Moncoq, F., Nemirov, K., Blanc, C., Planchais, C., et al. (2022) · bioRxiv · doi:10.1101/2022.01.30.478159
“for instance related to allergic reaction to polyethylene glycol (PEG) contained in mRNA vaccines, 86 have to be taken into the account [14].”
Background
The efficacy and safety of COVID-19 vaccine A protocol of systematic review and meta-analysis
Xue, X., Deng, Z., Li, N., Zhou, L., Wang, N., Xu, F., & Wang, X. (2021) · doi:10.37766/inplasy2021.3.0048
Safety profile of COVID-19 vaccines, preventive strategies, and patient management
Prabhu, M. M., Palaian, S., & Ansari, M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2078311 · Cited by 1
“The presence of past COVID-19 infection prior to vaccinations was also more likely to have increased the risk of anaphylaxis [51].”
Background
The adverse reactions to vaccines practice parameter 10 years on—what have we learned?
Wolfson, A. R. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.03.028
SARS-CoV-2 desde una perspectiva hematológica
Gálvez, K. (2022) · Medicina y Laboratorio · doi:10.36384/01232576.585
Psoriasiform Dermatitis Associated With the Moderna COVID-19 Messenger RNA Vaccine
Daneshbod (2022) · Cutis · doi:10.12788/cutis.0656
From Challenges to Opportunities and Open Questions
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_4
Multisystem inflammatory syndrome in children
Emeršič, N., & Avčin, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00015-3
Alergia y Covid-19
Isler, D., & Ma Antonieta Guzmán, M. (2021) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2021.69656
Immunity to Viral Pathogens and the Virome
Carlberg, C., Velleuer, E., & Molnár, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-27133-5_21
Current applications of biomolecules in biopharmaceuticals and drug discovery
Rastegari, A., Faghihi, H., & Mohammadi, Z. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91684-4.00023-2 · Cited by 1
Coronavirus Vaccines
Perlman, S. M., & Denison, M. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00017-7 · Cited by 2
Nanoscale Vaccines for the Prevention of COVID-19
Iqbal, M. J., Hamdani, T., Attarwala, H. Z., & Amiji, M. M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_13
Bullous hemorrhagic Sweet syndrome induced by SARS-CoV-2 Oxford AstraZeneca vaccinePreprint
Žagar, T., Hlača, N., Brajac, I., Massari, L. P., Peternel, S., & Kaštelan, M. (2024) · doi:10.22541/au.170667336.65881786/v1
Level of public’s awareness and acceptance towards COVID-19 vaccine
Ridzuan, A. R., Zin, A. M. A., Noor, N. H., Lokman, N. A., & Rahman, Z. A. (2024) · AIP conference proceedings · doi:10.1063/5.0182579
Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines
Lim, Q. Y., Lau, T. M., Lai, S. H. Y., Chua, G. T., Zhang, K., Lam, J. H. Y., Wong, W. H. S., Lau, Y., & Duque, J. S. R. (2024) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2024.100387
A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines
Arcolacı, A., Guidolin, L., Olivieri, E., Bilò, M. B., Bonadonna, P., Braschi, M. C., Crivellaro, M., Martignago, I., Matucci, A., Nalin, F., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127337
SARS-CoV-2 nucleocapsid protein delays cell cycle in S-phase
Liu, J., Liu, M., Yu, X., Wang, P., Guan, X., Huo, W., Zhang, J., Cui, M., Li, X., Zhou, X., et al. (2025) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2025.151671
Construction of Spleen-Accumulated Polysorbate 20-Containing Ionizable Lipid Nanoparticles for mRNA Delivery
Liu, H., Li, S., Chen, K., Yao, S., Tang, X., & Han, X. (2025) · Nanomaterials · doi:10.3390/nano15241844
“However, the immunogenicity, allergic reactions caused by lipid nanoparticles, as well as the diminished therapeutic efficacy observed upon repeated administration, are primarily attributed to PEGylated lipids [21–23].”
Additional file 1 of Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Chen, M., Yuan, Y., Zhou, Y., Deng, Z., Zhao, J., Feng, F., Zou, H., & Sun, C. (2021) · Figshare · doi:10.6084/m9.figshare.14913570
LNP-mRNA immunogenicity and toxicity
Thalla, M., Pasika, S. R., Bulusu, R., Reddy, D. S., Mundrathi, V., & Shukla, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00008-2
Optimising a mRNA Vaccine platform against HIV-1 : from the in vitro transcription design to envelope protein expression
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Premières étapes dans l'interaction hôte-pathogène : rôle de l'immunité locale et innée
Michel, M. (2022) · theses.fr (ABES) · doi:10.70675/4647f4d2zd802z40abza572z8ff228db523f
A phospholipid-like charge-reversible lipid for PEG-free, stable, and low-inflammatory mRNA lipid nanoparticles
Sha, P., Maeshima, S., Koide, H., Kanetaka, S., Koge, T., Kurosaki, T., & Asai, T. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104292
Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy
Repellin, M., Ugel, S., Sanctis, F. D., Coudert, L., Wang, T., Anselmi, C., Andretto, V., Scionti, I., Dimastromatteo, J., Sidi‐Boumedine, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115128 · Cited by 1
Advances and Challenges in Nanodelivery Systems for RNA Vaccines
Li, H., Zhao, Y., Yang, J., Guo, J., Cai, H., & Tong, A. (2026) · ACS Nano · doi:10.1021/acsnano.6c10327 · Cited by 2
Anaphylaxis to both pegfilgrastim and sargramostim in a patient with diffuse large B-cell lymphoma
Khamis, M. M., & Finnie, J. W. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-274279
Poly(2-oxazoline)s and poly(2-oxazine)s: An overview of stealth properties, pharmacokinetics, and immunogenicity
Jana, S., & Hoogenboom, R. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115975
Dual-State Tumor-Activated RNA Delivery for Tumor-Selective and Precision Therapy
Song, Y., Jiang, T., Shen, X., Chintrakulchai, W., Yanagida, K., 飯田恵介, Kobayashi, M., Muguruma, K., Honda, Y., Guo, H., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c16995
BindingDB Entry 50020276: Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.
BindingDB (2024) · UC San Diego · doi:10.7270/q279493g

Authors: Castells, M. C., & Phillips, E. J.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Castells, Mariana C.
ORCID: Castells, Mariana C.
Phillips, Elizabeth J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-02-18
Volume: 384
Issue: 7
Pages: 643-649
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra2035343
PMC: PMC7787218
OpenAlex: W3115737775
Cited by: 395
References: 17
Citations by year: 2026: 10 · 2025: 15 · 2024: 24 · 2023: 42 · 2022: 114 · 2021: 189
FWCI: 11.32
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: New England Journal of Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: COVID-19 vaccines, vaccine excipients, vaccine ingredients, package inserts, vaccine safety, vaccine production
MeSH terms: COVID-19, COVID-19 Vaccines, mRNA Vaccines, Anaphylaxis, Humans, Vaccines, Synthetic, Viral Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintaining Safety with SARS-CoV-2 Vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks